The stock of Histogenics Corp (NASDAQ:HSGX) is a huge mover today! About 160,406 shares traded hands or 442.66% up from the average. Histogenics Corp (NASDAQ:HSGX) has risen 3.39% since April 8, 2016 and is uptrending. It has underperformed by 2.26% the S&P500.
The move comes after 9 months negative chart setup for the $33.55M company. It was reported on Nov, 10 by Barchart.com. We have $1.94 PT which if reached, will make NASDAQ:HSGX worth $4.03 million less.
Histogenics Corp (NASDAQ:HSGX) Ratings Coverage
Out of 5 analysts covering Histogenics Corp (NASDAQ:HSGX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Histogenics Corp has been the topic of 8 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Needham maintained the shares of HSGX in a report on Friday, November 13 with “Buy” rating. The company was upgraded on Friday, August 12 by BTIG Research. The company was maintained on Monday, September 19 by Needham. The company was downgraded on Thursday, August 27 by Zacks. On Friday, November 13 the stock rating was downgraded by BTIG Research to “Neutral”. The stock has “Market Perform” rating given by William Blair on Wednesday, September 7. The firm has “Buy” rating given on Friday, November 13 by Canaccord Genuity.
According to Zacks Investment Research, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.”
More recent Histogenics Corp (NASDAQ:HSGX) news were published by: Reuters.com which released: “BRIEF-Histogenics Corp posts Q3 loss per share of $0.70” on November 10, 2016. Also Quotes.Wsj.com published the news titled: “Histogenics Corp. HSGX (US: Nasdaq)” on December 01, 2014. Reuters.com‘s news article titled: “BRIEF-Histogenics Corp files for 26.8 mln common stock offering” with publication date: October 05, 2016 was also an interesting one.
HSGX Company Profile
Histogenics Corporation, incorporated on July 14, 2006, is a regenerative medicine company. The Firm is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The Firm uses regenerative medicine platform to develop its products. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company’s TEP is designed to mimic the conditions found in a joint so that the implant is prepared to begin functioning like normal healthy cartilage prior to implantation. When NeoCart is implanted, a bioadhesive is used to anchor NeoCart in the cartilage injury and seal the implant to the surrounding native cartilage interface.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.